Arrowhead Pharmaceuticals (ARWR) FCF Margin (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly FCF Margin came in at 111.04% in Q1 2026, up 2816.0% YoY from 3.81% in Q1 2025, and up 2486.96% on a QoQ basis from 4.29% in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) FCF Margin (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of FCF Margin data on file, last reported at 111.04% in Q1 2026.
- Quarterly FCF Margin rose 2816.0% year-over-year to 111.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.58% (down 634.0% YoY) and the FY2025 annual result came in at 21.61%, up 1703992.0% from the prior year.
- FCF Margin improved to 111.04% in Q1 2026, from 4.29% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 188.46% in Q2 2023 to a low of 5953.84% in Q4 2024.
- A 5-year average of 945.25% and a median of 111.64% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin slumped 506898 bps — and 2025, when it soared 595813 bps.
- Tracing ARWR's FCF Margin over 5 years: stood at 182.95% in 2022, then sank by 2771 bps to 5251.93% in 2023, then dropped by 13 bps to 5953.84% in 2024, then jumped by 100 bps to 4.29% in 2025, then soared by 2487 bps to 111.04% in 2026.
- The last three FCF Margin figures came in at 111.04% (Q1 2026), 4.29% (Q4 2025), and 8.02% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -240.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -240.95% |
| Mar 31, 2026 | 111.04% |
| Dec 31, 2025 | 4.29% |
| Sep 30, 2025 | 8.02% |
| Jun 30, 2025 | -512.31% |
| Mar 31, 2025 | 82.88% |
| Dec 31, 2024 | -5,953.84% |
| Dec 31, 2023 | -5,251.93% |
| Sep 30, 2023 | -1,161.95% |
| Jun 30, 2023 | 188.46% |
| Mar 31, 2023 | -40.33% |
| Dec 31, 2022 | -182.95% |
| Sep 30, 2022 | -321.29% |
| Jun 30, 2022 | -241.73% |
| Mar 31, 2022 | 38.19% |
| Dec 31, 2021 | -244.49% |
| Sep 30, 2021 | -84.18% |
| Jun 30, 2021 | -73.09% |
| Mar 31, 2021 | 782.38% |
| Dec 31, 2020 | -202.76% |